

May 28, 2025

To,
The Chief General Manager
Listing Operation,
BSE Limited,
20th Floor, P. J. Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code: 524743

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 28th May, 2025

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (28/05/2025):

1. Financial Results

Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended 31/03/2025, Statement of Assets & Liabilities and Statement of Cash Flow for the year ended on March 31st 2025 along with Auditors Report (Standalone and Consolidated) thereon and Declaration in respect of Audit Report (Standalone and Consolidated) with unmodified opinion under Regulation 33(3)(d) of the Listing Regulations are enclosed herewith as **Annexure-1**.

We hereby confirm and declare that the Statutory Auditors of the Company i.e., M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai, have issued their audit report on Standalone and Consolidated Financial Statements of the Company for the year ended 31st March 2025 with an unmodified opinion.

2. Dividend:

The Board decided to recommend to the members a final dividend of Rs. 0.05/- per equity share for the financial year ended 31st March 2025, which shall be paid/ dispatched within 30 days from the date of ensuing Annual General Meeting ('AGM'), if declared and approved by the members at the AGM.

3. Appointment of Auditors:

- a. On the recommendation of Audit Committee, approved the re-appointment of M/s. **Bilimoria Mehta & Co** (FRN: 101490W), as the Statutory Auditors of the Company, for a second term of consecutive five years, from the conclusion of the thirty second Annual General Meeting till the conclusion of thirty seven Annual General Meeting, subject to approval of the Members at the ensuing Annual General Meeting. The Statutory Auditors presently hold office till the conclusion of the thirty second Annual General Meeting, details of the appointment is enclosed as **Annexure -2**.
- b. On the recommendation of Audit Committee, the Board of Directors in their meeting held today approved the appointment of the Internal Auditors, S. Ramanand Aiyer & Co., Chartered Accountants, for the Financial Year 2025-26.

4. Listing on National Stock Exchange of India (NSE):

The Board of Directors on the recommendations of Audit Committee have recommended the for the Listing on the Main Board of National Stock Exchange of India.

The date of the ensuing Annual General Meeting will be intimated to the Stock Exchanges in due course of time.

The Board Meeting commenced at 7.30 PM (IST) and concluded at 8.10 PM (IST)

Please take on record.

Thanking You,
Yours Truly,
Thanking You,

For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN
CHAIRMAN & MANAGING DIRECTOR



FISCHER MEDICAL VENTURES LIMITED
(formerly known as Fischer Chemic Limited)
CIN: L86900AP1993PLC118162

Regd Off: No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Visakhapatnam, Andhra Pradesh, India, 530044
Corp off: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006, India
Email: cs@fischermv.com | Website: www.fischermv.com

Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended 31.03.2025 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs											
SL NO	PARTICULARS	STANDALONE					CONSOLIDATED				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue From Operations	521.97	-	1,134.02	521.97	1,152.83	4,917.42	1,174.85	2,079.32	11,069.87	2,098.13
II	Other Income	64.93	86.58	72.35	345.70	75.05	14.87	37.81	46.78	149.20	50.12
III	Total Income (I + II)	586.90	86.58	1,206.37	867.67	1,227.87	4,932.29	1,212.66	2,126.10	11,219.07	2,148.26
IV	Expenses										
	Cost Of Materials Consumed	-	-	1,072.36	-	1,072.36	-	-	1,573.80	-	1,573.80
	Purchase of Traded Assets	454.56	-	-	461.06	-	3,472.30	217.71	7.87	9,528.18	7.87
	Changes in inventories of finished goods, by-products and work in progress	-	-	-	(6.50)	-	458.75	536.19	63.74	(369.22)	63.74
	Employee Benefits Expense	4.74	1.40	1.29	12.84	5.50	93.58	74.64	33.86	258.13	38.10
	Depreciation and Amortisation Expenses	9.86	2.76	0.06	12.72	0.08	51.03	55.71	18.19	163.28	18.21
	Finance Costs	12.41	0.75	-	13.17	1.58	22.63	6.69	5.18	46.68	6.76
	Other Expenses	218.48	19.67	70.01	278.30	94.49	642.46	296.71	148.18	1,321.10	228.66
	Total Expenses	700.05	24.58	1,143.72	771.59	1,174.01	4,740.75	1,187.65	1,850.82	10,948.15	1,937.14
V	Profit / (Loss) Before Exceptional Items & Tax (III - IV)	(113.15)	62.00	62.65	96.08	53.87	191.54	25.01	275.28	270.92	211.12
VI	Share of profit/(loss) of Associates	-	-	-	-	-	(10.32)	(12.57)	-	(48.65)	-
VI	Exceptional Items	-	-	-	-	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	(113.15)	62.00	62.65	96.08	53.87	181.22	12.44	275.28	222.27	211.12
VIII	Tax Expense										
	Current Tax	(3.40)	(42.00)	(3.00)	(57.40)	(3.00)	(59.35)	(42.00)	(3.00)	(113.35)	(3.00)
	Deferred Tax (Asset) / Liability	27.50	0.17	(0.02)	27.64	(10.59)	9.35	0.17	(13.76)	11.87	(24.33)
IX	Profit / (Loss) For The Period From Continuing Operations (VII - VIII)	(89.05)	20.17	59.63	66.32	40.28	131.22	(29.39)	258.52	120.79	183.79
X	Profit / (Loss) From Discontinued Operations	-	-	-	-	-	-	-	-	-	-
XI	Tax Expense Of Discontinued Operations	-	-	-	-	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinued Operations After Tax (X - XI)	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) For The Period (IX + XII)	(89.05)	20.17	59.63	66.32	40.28	131.22	(29.39)	258.52	120.79	183.79
XIV	Items That Will Not Be Reclassified To Profit / (Loss)										
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	-	-	-	-	-	(0.78)	-	-	(0.78)	-
	(ii) Income Tax Relating On Above	-	-	-	-	-	-	-	-	-	-
	(iii) Equity Instruments Through Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income - Total	-	-	-	-	-	-	-	-	-	-
XV	Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))	(89.05)	20.17	59.63	66.32	40.28	130.44	(29.39)	258.52	120.01	183.79
XVI	Paid Up Equity Share Capital (Face Value Re.1/-)	6,380.15	5,350.00	5,350.00	6,380.15	5,350.00	6,380.15	5,350.00	5,350.00	6,380.15	5,350.00
XVII	Other Equity				24166.26					24350.14	
XVIII	Earnings Per Share (EPS) From Continuing Operations & Discontinued Operations (In Rs.)										
	Basic	(0.06)	0.04	0.15	0.05	0.36	0.09	(0.05)	0.65	0.22	1.65
	Diluted	(0.06)	0.04	0.15	0.04	0.36	0.09	(0.05)	0.64	0.22	1.08

Notes:

- These audited consolidated financial results relate to Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) (the 'Company'), and its Subsidiaries (together the 'Group'), and Associates are prepared by applying Ind AS 110 - "Consolidated Financial Statements",
- The above Audited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 28th May 2025
- During the second quarter, the Company completed the incorporation of Wondertech Medical Solutions Pvt. Ltd., Fischer Hospitality Sdn. Bhd., FMV International Ventures PTE Ltd., and FMV Healthcare PTE Ltd. These entities have been considered for consolidation purposes
- During the fourth quarter, the Company completed the incorporation of subsidiary company in the name of Nanyang Biologics (India) P Ltd. The entity have been considered for consolidation purposes.
- Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification.
- The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company.
- The figures for the quarter ended 31.03.2025 and 31.03.2024 are balancing figure between Audited Figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year.
- The Statutory Auditor of the Company audited the above Standalone and Consolidated Financial Results for the Year ended 31.03.2025 and the Audit Report with an unmodified opinion was placed before the Board.

// BY ORDER OF THE BOARD //



For and on behalf of the Board
Fischer Medical Ventures Limited
(Formerly known as Fischer Chemic Limited)
RAVINDRAN GOVINDAN
Digitally signed by RAVINDRAN GOVINDAN
Date: 2025.05.28 22:46:54 +05'30'
Chairman & Managing Director
DIN : 03137661

Date: 28.05.2025

May 28, 2025

Declaration under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

I, RAVINDRAN GOVINDAN, Chairman & Managing Director of FISCHER MEDICAL VENTURES LIMITED (Formerly known as Fischer Chemic Limited) (CIN: L86900AP1993PLC118162) having its Registered Office at Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032, hereby declare that the Statutory Auditor M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai, Chennai (FRN: 101490W) have issued an Audit Report (Standalone and Consolidated) with unmodified opinion on Audited Financial Results of the Company for the Quarter and Financial Year ended 31/03/2025. This declaration is given in compliance to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your record and oblige.

Thanking You,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)

RAVINDRAN
GOVINDAN

Digitally signed by
RAVINDRAN GOVINDAN
Date: 2025.05.28 21:35:56
+05'30'

RAVINDRAN GOVINDAN

CHAIRMAN & MANAGING DIRECTOR



Independent Auditor's Report on Standalone Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

Opinion

We have audited the accompanying statement of Standalone Audited Annual Financial Results ('the Statement') of **Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)** for the year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time.

1. In our opinion and to the best of our information and according to the explanations given to us, the Statement :

- (i) Is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, and
- (ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company year ended 31 March 2025.

Basis for Opinion

- 2. We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under Section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion

Responsibilities of Management and Those Charged with Governance for the Statement

3. This Statement has been prepared on the basis of the standalone annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit or loss and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
4. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.
5. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

6. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under Section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
7. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.
 - Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.
8. Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.
9. We communicate with those charged with governance regarding among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter


11. The Statement includes the financial results for the quarter ended 31 March 2025, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.


Our opinion is not modified in respect of above matters.




For Bilimoria Mehta & Co
Chartered Accountants
Firm Registration No.: 101490W



Prakash Mehta
Partner
Membership no. 030382
UDIN: 25030382BMIIIIZ1842
Place of Signature: Mumbai
Date: May 26, 2025

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) CIN : L86900AP1993PLC118162 Standalone Balance Sheet As At March 31st, 2025 (Amount in lakhs)		
Particulars	As At 31-03-2025	As At 31-03-2024
Assets		
(1) Non-Current Assets		
Property, Plant & Equipment	0.38	0.58
ROU Asset	67.55	
Deferred Tax Asset (Net)	27.63	
Other Non Current Assets	62.30	
Financial Assets		
(i) Investments	29,435.94	4,128.26
(ii) Other Financial asset	3,501.90	
Total Non-Current Assets	33,095.68	4,128.84
(2) Current assets		
(a)Inventories	6.50	-
(b) Financial assets		
(i) Trade receivables	1,707.68	1,270.10
(ii) Cash and cash equivalents	28.71	0.38
(iii) Other Current Financial Asset		
-Loans	142.94	3,777.74
-Other Current Financial Asset	567.66	0.58
(c) Current Tax Asset(Net)	-	5.51
(d) Other Current Assets	301.25	-
Total Current Assets	2,754.74	5,054.31
Total Assets	35,850.43	9,183.16
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	6,380.15	5,350.00
(b) Other Equity		
Reserve & Surplus	24,166.26	2,530.79
(c)Money received against share warrants	3,022.10	87.15
Total Equity	33,568.51	7,967.94
Liabilities		
(1) Non-Current Liabilities		
(a) Deferred Tax Liability		0.20
(b) Financial Liabilities		
(i) Lease Liabilities	1,569.71	
Total Non-Current Liabilities	1,569.71	0.20
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Lease Liabilities	637.88	-
(ii) Trade payables		
total outstanding dues of micro enterprises and small enterprises	2.05	0.31
total outstanding dues of creditors other than micro enterprises and small enterprises	37.36	1,203.43
(iii)Other Financial liabilities	13.82	2.56
(b) Other Current Liabilities	-	8.90
(c) Current Tax Liability	21.10	-
Total Current Liabilities	712.21	1,215.20
Total Equity and Liabilities	35,850.43	9,183.16
The accompanying notes are an integral part of the financial statements. As per our report of even date For M/s Bilimoria Mehta & Co. Chartered Accountants FRN: 101490W PRAKASH RAMNIKAL MEHTA 21-11-52 +05'30' CA Prakash Mehta Partner M.No: 030382 Date: 28th May 2025 UDIN: 25030382BMIII1842		
<div> For and on behalf of the Board Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)  RAVINDRAN GOVINDAN Digitally signed by RAVINDRAN GOVINDAN Date: 2025.05.28 19:54:31 +05'30' Managing Director DIN: 03137661 </div>		

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) CIN : L86900AP1993PLC118162 STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March 2025 (Amount in lakhs)						
Particulars		Quarter Ended			Year ended	
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
		Audited	Unaudited	Audited	Audited	Audited
I)	Revenue From Operations	521.97	-	1,134.02	521.97	1,152.83
II)	Other Income	64.94	86.58	72.35	345.70	75.05
III)	Total Income (I+II)	586.90	86.58	1,206.36	867.67	1,227.87
IV)	Expenses :					
	Purchase of Traded Goods	454.56	-	1,072.36	461.06	1,072.36
	Changes in inventories of finished goods, by-products and work in progress	-	-	-	(6.50)	-
	Employee Benefit expenses	4.74	1.40	1.29	12.84	5.50
	Depreciation and Amortization Expenses	9.86	2.76	0.06	12.72	0.08
	Finance Cost	12.41	0.75	-	13.17	1.58
	Other Expenses	218.48	19.68	70.01	278.30	94.49
	Total Expenses (IV)	700.05	24.58	1,143.72	771.58	1,174.01
V)	Profit (Loss) Before exceptional and tax (III-IV)	(113.15)	62.00	62.65	96.08	53.86
VII)	Share of Loss from Associate					
	- The Therapy Platform Pte Ltd		-	-		-
	- Bluesim tech pte ltd FS		-	-		-
	Profit/(loss) before exceptional items and tax (VII + VIII)	(113.15)	62.00	62.65	96.08	53.86
VI)	Exceptional Items		-	-		-
	Profit before tax (V-VI)	(113.15)	62.00	62.65	96.08	53.87
VIII)	Tax Expenses					
	i) Current Tax	2.00	(42.00)	(3.00)	(52.00)	(3.00)
	ii) Deferred Tax	27.50	0.17	(0.02)	27.64	(10.59)
	iii) Tax pertaining to previous year	(5.40)			(5.40)	
IX)	Profit (Loss) from Continuing Operations (VII-VIII)	(89.05)	20.17	59.63	66.32	40.28
XIII)	Profit (Loss) for the period (XI+XII)	(89.05)	20.17	59.63	66.32	40.28
XIV)	Other Comprehensive income;					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV)	Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (XIII-XIV)	(89.05)	20.17	59.63	66.32	40.28
XVI)	Earnings per Equity Shares					
	1) Basic	(0.06)	0.04	0.15	0.05	0.36
	2) Diluted	(0.06)	0.04	0.15	0.04	0.36
	Summary of significant accounting policies					
	Notes to accounts					
As per our report of even date For M/s Bilimoria Mehta & Co. Chartered Accountants FRN: 101490W PRAKASH RAMNIKAL MEHTA MEHTA CA Prakash Mehta Partner M.No: 030382 Date: 28th May 2025 Place of Signature: Mumbai UDIN: 25030382BMHIZ1842						
For and on behalf of the Board Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)  RAVINDRAN GOVINDAN Digitally signed by RAVINDRAN GOVINDAN Date: 2025.05.28 19:54:44 +05'30' Managing Director DIN: 03137661						

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) CIN : L86900AP1993PLC118162 Cash Flow Statement as at March 31, 2025		
(Amount in lakhs)		
PARTICULARS	For the year ended 31st March 2025	For the year ended 31st March 2024
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit /(Loss) before tax and Extra Ordinary items	96.08	53.87
<u>Adjustment for:-</u>		
Finance Cost	-	1.58
Depreciation on fixed assets	0.21	0.08
Depreciation on Deferred Rent	1.70	-
Depreciation on ROU Asset	10.81	-
Interest Income on Unwinding of Security Deposit	(1.42)	-
Interest on Net Receivable (Sublease)	(9.68)	-
Loss on Lease Recognition	129.71	-
Interest Income on FD	(3.64)	-
Provision for Doubtful Debts	11.90	-
Interest on Lease Liability	13.17	-
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	248.83	55.52
<u>Adjustment for:-</u>		
(Increase)/decrease Trade and other receivables	(449.48)	(1,253.04)
Increase/(decrease) Trade Payables	(1,164.33)	1,202.33
Increase/(decrease) Other Financial Current Liabilities	11.26	0.15
Increase/(decrease) Other Current Liabilities	(8.90)	7.94
(Increase)/decrease Inventories	(6.50)	-
(Increase)/decrease Others Current Assets	(302.95)	-
(Increase)/decrease Non Current Assets	(62.30)	-
(Increase)/decrease Non Current financial Assets	(164.67)	-
(Increase)/decrease Current financial Assets	(350.80)	(0.09)
CASH GENERATED FROM OPERATIONS	(2,498.67)	(42.71)
Direct Taxes Paid	(30.79)	(4.86)
I NET CASH FLOW FROM OPERATING ACTIVITIES	(2,280.64)	7.96
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(0.00)	(0.66)
Loans & Advances Repaid	3,634.80	(3,777.74)
Interest Income on Fixed Deposit	1.19	-
Investment In Subsidiaries	(25,045.68)	-
Investment In Fixed Deposit	(1,890.13)	-
Sale of Fixed Deposit	120.63	-
II NET CASH USED IN INVESTING ACTIVITIES	(23,179.20)	(3,778.40)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of shares	3,965.10	3,826.00
Proceeds/(Repaid) from Long term Borrowings	-	(57.17)
Proceeds of premium from Issue of shares	23,075.47	-
Expenses on account of issue of shares written off from securities premium	(1,506.31)	-
Payment of Lease Rent	(46.09)	-
Finance cost paid	-	(1.58)
III NET CASH USED IN FINANCING ACTIVITIES	25,488.16	3,767.25
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	28.33	(3.20)
<u>Add:- CASH & CASH EQUIVALENTS AS AT BEGNNING</u>	<u>0.38</u>	<u>3.58</u>
CLOSING BALANCE OF CASH & CASH EQUIVALENTS	28.71	0.38
The accompanying notes are an integral part of the financial statements.		
As per our report of even date		
<p>Note 1.The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7- Statement of Cash flows.</p>		
For M/s Bilimoria Mehta & Co. Chartered Accountants FRN: 101490W  CA Prakash Mehta Partner M.No: 030382 Date: 28th May 2025 Place of Signature: Mumbai UDIN: 25030382BMHIZ1842		For and on behalf of the Board Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) RAVINDRAN GOVINDAN  Managing Director DIN : 03137661

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of

Fischer Medical Ventures Limited

(Formerly known as Fischer Chemic Limited)

Opinion

We have audited the accompanying consolidated annual financial results ('the Statement') of **Fischer Medical Ventures Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), for the quarter ended 31st March 2025 and for the year ended March 31st March 2025, attached herewith, being submitted by the Holding Company pursuant to the requirements of [Regulation 33] of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

1. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate audited financial results and on the other financial information of the subsidiaries as referred to in paragraph 11 below, the Statement:

(i) Includes the annual financial results of its subsidiaries and associates (Refer Annexure 1)

(ii) And presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and

(iii) Gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit/loss after tax and other comprehensive income and other financial information of the Group, for the), for the quarter ended 31st March 2025 and for the year ended March 31st March 2025

Basis for Opinion

2. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in *the Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group, its associates and joint ventures, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and

the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 11 of the Other Matter section below is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Statement

3. The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit or loss and other comprehensive income, and other financial information of the Group including its associates and joint ventures in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and its associates and joint ventures, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
4. In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors/ management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
5. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

Auditor's Responsibilities for the Audit of the Statement

6. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

7. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.
 - Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the Consolidated Financial Results of the Company to express an opinion on the Consolidated Financial Results.
8. We communicate with those charged with governance of the Holding Company, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
9. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

10. We also performed procedures in accordance with SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019, issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

11. We did not audit the annual financial statements/ financial information/ financial results of it's subsidiaries included in the Statement, whose financial information reflects total assets of ₹ 50,03,17,130.33 as at 31st March 2025, total income of ₹ 1,06,60,37,699.24 total net profit after tax of ₹ 42,98,905.97, total comprehensive income/(loss) of ₹ 42,20,959.97, and cash flows (net) of ₹ 16,21,29,741, for the year ended on that date, as considered in the respective audited separate annual financial result of the entities included in the group. These Annual Financial results have been audited by others auditors whose audit report(s) have been furnished to us by the management, and our opinion in so far as its relates to the amounts and disclosures included in the respect of these subsidiary is based solely on the audit report(s) of such other auditors, and the procedures performed by us as stated in paragraph 9 above.
12. Standalone financial statement of 7 company whose financial statement/financial information that reflect total assets of Rs. 3,31,000 and net assets of Rs. 1,78,000 as at 31 March 2025, total revenues of Rs. Nil and net cash inflows Rs. 1,00,000, total net loss of subsidiaries Rs. 1,78,000 and total net loss of associates Rs. 48,65,319 for the year ended on that date, as considered in the consolidated financial statements, have not been audited. This unaudited standalone financial statement / financial information have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, and our report in terms of sub-sections (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiary is based solely on such unaudited standalone financial statement / financial information. In our opinion and according to the information and explanations given to us by the Management, this standalone financial statement / financial information is not material to the Group.

Our opinion is not modified in respect of above matter (s) with respect to our reliance on the work done by and the reports of the other auditors.

For Bilimoria Mehta & Co
Chartered Accountants
Firm Registration No.: 101490W



Prakash Mehta
Partner
Membership no. 030382
UDIN: 25030382BMIIJB7016
Place of Signature: Mumbai
Date: May 28, 2025

Annexure 1

<u>Sr no</u>	<u>Particulars</u>	<u>Stakes</u>	<u>Status</u>	
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary	Audited by SMPB & Co.
2	Time Medical Philippines (Subsidiary of Time Medical International Ventures (India) Private Limited)	75%	Step Subsidiary of Subsidiary	Mark Jayson Uy
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of Subsidiary	Unaudited
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of Subsidiary	Unaudited
5	Flynncare HealthCare Innovations Private Limited	100%	Subsidiary of Fischer Medical Ventures Limited	Audited by SMPB & Co.
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer Medical Ventures Limited	Unaudited
7	Fischer Hospitality Sdn. Bdn.	60%	Subsidiary of Fischer Medical Ventures Limited	Unaudited
8	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited	Unaudited
9	FMV HealthCare PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited	Unaudited
10	Nanyang Biologics (India) Private Limited	60%	Subsidiary of Fischer Medical Ventures Limited	Unaudited

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900AP1993PLC118162

BALANCE SHEET AS AT March 31, 2025

Particulars	As At 31st March 2025	As At 31st March 2024
Assets		
(1) Non-Current Assets		
Property, Plant & Equipment	1,442.51	935.14
Capital Work in progress	111.12	-
Right of use Asset	417.91	314.30
Goodwill	527.70	221.52
Deferred Tax Asset (Net)	38.74	-
Other Non-Current Assets	62.30	-
Financial Assets	-	-
(i) Investments	1,077.18	120.63
(ii) Other non - current assets	5,530.94	-
Total Non-Current Assets	9,208.38	1,591.60
(2) Current assets		
(a) Inventories	916.37	447.55
(b) Financial assets	-	-
(i) Trade receivables	7,606.63	2,286.96
(ii) Cash and cash equivalents	10,426.28	94.83
(iii) Bank balances other than cash and cash equivalents	14,709.38	3,699.77
(iv) Other Current Financial Asset	-	-
-Loans and advances	0.00	-
-Other Current Financial Asset	2,395.95	305.31
(c) Current Tax Asset(Net)	-	-
(b) Other Current Assets	474.04	206.14
Total Current Assets	36,528.64	7,040.56
Total Assets	45,737.02	8,632.17
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	6,380.15	5,350.00
(b) Other Equity	24,350.14	2,675.30
(c) Non Controlling Interest	34.15	-
Reserve & Surplus	-	2,675.30
(d) Money received against share warrants	3,022.10	87.15
Total Equity	33,786.54	8,112.45
Liabilities		
(1) Non-Current Liabilities		
(a) Deferred Tax Liability	39.27	12.40
(b) Financial Liabilities	-	-
(i) Borrowings	1,972.65	-
(ii) Lease Liabilities	1,773.23	125.10
(iii) Other Financial Liabilities	8.51	-
Total Non-Current Liabilities	3,793.67	137.50
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Short Borrowings	4,067.46	-
Lease Liabilities	723.88	42.60
(ii) Trade payables		
total outstanding dues of micro enterprises and small enterprises	73.26	79.88
total outstanding dues of creditors other than micro enterprises and small enterprises		
(iii) Other Financial liabilities	1,992.22	135.67
(b) Other Current Liabilities	54.37	102.80
(c) Current Tax	1,165.62	20.37
(d) Provisions	21.10	-
Total Current Liabilities	58.90	0.90
Total Current Liabilities	8,156.82	381.32
Total Equity and Liabilities	45,737.02	8,632.17

The accompanying notes are an integral part of the financial statements. As per our report of even date

For M/s Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W











CA Prakash Mehta
Partner
M.No: 030382
Date: 28th May 2025
UDIN:25030382BMILJB7016

For and on behalf of the Board
Fischer Medical Ventures Limited
(Formerly known as Fischer Chemic)



Managing Director
DIN : 03137661

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)						
CIN : L86900AP1993PLC118162						
STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March, 2025						
(Amount in lakhs)						
Particulars		Quarter Ended			Year ended	
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
		Audited	Audited	Audited	Audited	Audited
I)	Revenue From Operations	4,917.42	1,174.85	2,079.32	11,069.87	2,098.13
II)	Other Income	14.87	37.81	46.78	149.20	50.12
III)	Total Income (I+II)	4,932.28	1,212.67	2,126.10	11,219.07	2,148.25
IV)	Expenses :					
	Cost of Material Consumed	-		1,573.80	-	1,573.80
	Purchase of Traded Goods	3,472.30	217.71	7.87	9,528.18	7.87
	Changes in inventories of finished goods, by-products and work in progress	458.75	536.19	63.74	(369.22)	63.74
	Direct Expenses					
	Employee Benefit expenses	93.58	74.64	33.86	258.13	38.10
	Depreciation and Amortization Expenses	51.03	55.71	18.19	163.28	18.21
	Finance Cost	22.63	6.69	5.18	46.68	6.76
	Other Expenses	642.46	296.71	148.18	1,321.10	228.66
	Total Expenses (IV)	4,740.76	1,187.66	1,850.82	10,948.15	1,937.13
V)	Profit (Loss) Before exceptional and tax (III-IV)	191.52	25.01	275.28	270.92	211.12
VII)	Share of Loss from Associate					
	- The Therapy Platform Pte Ltd	(1.53)	(1.93)	-	(13.29)	-
	- Bluesim tech pte ltd FS	(8.79)	(10.64)	-	(35.36)	-
	Profit/(loss) before exceptional items and tax (VII + VIII)	181.21	12.44	275.28	222.27	211.12
VI)	Exceptional Items			-	-	-
	Profit before tax (V-VI)	181.21	12.44	275.28	222.27	211.12
VIII)	Tax Expenses					
	i) Current Tax	(53.95)	(42.00)	(3.00)	(107.95)	(3.00)
	ii) Deferred Tax	9.35	0.17	(13.76)	11.87	(24.33)
	iii) Tax pertaining to previous year	(5.40)			(5.40)	
IX)	Profit (Loss) from Continuing Operations (VII-VIII)	131.22	(29.39)	258.52	120.79	183.79
XIII)	Profit (Loss) for the period (XI+XII)	131.22	(29.39)	258.52	120.79	183.79
XIV)	Other Comprehensive income;					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.78)	-	-	(0.78)	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (XIII-XIV)	130.44	(29.39)	258.52	120.01	183.79
XV)						
XVI)	Profit for the year attributable to :					
	Owners of the company	149.69			147.38	183.79
	Non controlling Interest	(19.25)			(27.37)	
XVII)	Earnings per Equity Shares					
	1) Basic	0.09	(0.05)	0.65	0.22	1.65
	2) Diluted	0.09	(0.05)	0.64	0.22	1.08
	Summary of significant accounting policies					
	Notes to accounts					
As per our report of even date						
For M/s Bilimoria Mehta & Co. Chartered Accountants FRN: 101490W			For and on behalf of the Board Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)			
  CA Prakash Mehta Partner M.No: 030382 Date: 28th May 2025 UDIN:25030382BMILJB7016			  Managing Director DIN : 03137661			
Notes:						
1. These audited consolidated financial results relate to Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) (the 'Company'), and its Subsidiaries (together the 'Group'), and Associates are prepared by applying Ind AS 110 - "Consolidated Financial Statements",						
2. The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved on 27-05-2025 and the Board of Directors at their respective meetings held on 28-05-2025						
3. During the second quarter, the Company completed the incorporation of Wondertech Medical Solutions Pvt. Ltd., Fischer Hospitality Sdn. Bhd., FMV International Ventures PTE Ltd., and FMV Healthcare PTE Ltd. These entities have been considered for consolidation purposes .						
4. During the fourth quarter, the Company completed the incorporation of subsidiary company in the name of Nanyang Biologics (India) P Ltd. The entity have been considered for consolidation purposes.						

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) CIN : L86900AP1993PLC118162 Cash Flow Statement as at March 31, 2025			(Amount in lakhs)
PARTICULARS	For the year ended 31-03-2025	For the year ended 31-03-2024	
A CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit /(Loss) before tax and Extra Ordinary items	222.27	211.12	
<u>Adjustment for:-</u>			
Finance Cost	46.68	2.68	
Depreciation	65.80	9.05	
Depreciation on ROU	14.67	9.16	
Interest On lease liability	32.03	4.08	
Interest on Net Receivable (Sublease)	(9.68)	-	
Loss on Lease Recognition	129.71	-	
Provision for Doubtful Debts	18.54	-	
Interest on Fixed Deposits	(77.21)	-	
Profit on sale of Scrap	(5.24)	-	
Loss from Associates	48.65	-	
Others	(5.07)	-	
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	481.15	236.09	
<u>Adjustment for:-</u>			
(Increase)/decrease inventories	(340.68)	1,752.11	
(Increase)/decrease Trade and other receivables	(5,338.21)	(3,470.94)	
Increase/(decrease) Trade Payables	1,418.08	993.89	
Increase/(decrease) Other Financial Current Liabilities	(51.25)	100.39	
Increase/(decrease) Other Current Liabilities	1,145.25	(8.69)	
(Increase)/decrease Others current Financial Assets	(1,878.24)	(294.90)	
(Increase)/decrease Others Non Current financial Assets	(3,684.62)	-	
(Increase)/decrease Others Current Assets	(247.32)	(38.29)	
(Increase)/decrease Others Non Current Assets	(55.17)	-	
Increase/(decrease) Other Financial Liabilities	8.51	-	
Increase/(decrease) Provisions	58.00	-	
Others	(48.44)	-	
CASH GENERATED FROM OPERATIONS	(9,014.08)	(966.43)	
Direct Taxes Paid	(92.25)	(4.86)	
I NET CASH FLOW FROM OPERATING ACTIVITIES	(8,625.18)	(735.20)	
B CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Fixed Assets	(598.72)	(48.49)	
Purchase of Investments	(12,014.81)	(3,090.00)	
Interest Received on Fixed Deposit	77.21	(0.08)	
II NET CASH USED IN INVESTING ACTIVITIES	(12,536.31)	(3,138.57)	
C CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Issue of shares	3,965.10	3,826.00	
Process from securities premium from issue of shares	21,569.15	(60.44)	
Proceeds/(Repaid) from Long term Borrowings	5,987.92	(57.17)	
Finance cost paid and Rent Paid	(29.72)	(2.68)	
III NET CASH USED IN FINANCING ACTIVITIES	31,492.44	3,705.72	
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	10,330.95	(168.07)	
<u>Add:- CASH & CASH EQUIVALENTS AS AT BEGINNING</u>	<u>94.83</u>	<u>3.58</u>	
<u>less - CASH & CASH EQUIVALENTS ACQUIRED FROM SUBSIDIARIES</u>	<u>0.50</u>	<u>259.32</u>	
CLOSING BALANCE OF CASH & CASH EQUIVALENTS (Refer Note 2)	10,426.28	94.83	
As per our report of even date			
Note 1. The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7-			
For M/s Bilimoria Mehta & Co. Chartered Accountants FRN: 101490W   CA Prakash Mehta Partner M.No: 030382 Date: 28th May 2025 UDIN:25030382BMILJB7016		For and on behalf of the Board Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)  Managing Director DIN : 03137661	

Annexure -2

Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015

S No.	Particulars	Details
1	Name of Audit firm	Bilimoria Mehta & Co (FRN: 101490W), Chartered Accountants
2	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment
3	Date of appointment/cessation (as applicable)	Ensuing Annual General Meeting of the Company.
4	Term of Appointment	Subject to the approval of the Shareholders, reappointed for the second term of five consecutive years commencing from the conclusion of ensuing 32 nd Annual General Meeting of the Company, till the conclusion of the 37 th Annual General Meeting of the Company to be held in the year 2030.
5	Brief Profile	Bilimoria Mehta & Co. (BMAC) is a chartered accountancy firm established in 1977, with a team of over 200 professionals across Mumbai, Delhi, Kolkata, and Chennai. The firm offers a wide range of services including audit and assurance, tax consulting (direct and indirect), advisory on corporate laws, FEMA, management consultancy, transaction advisory, and banking consultancy. BMAC emphasizes a solution-oriented and collaborative approach, providing tailored services with partner-level attention. Their expertise spans industries like banking, manufacturing, IT, hospitality, telecom, and pharmaceuticals. The firm is known for its responsiveness, agility, and experience drawn from multinational accounting backgrounds, delivering value beyond standard engagements
6	Disclosure of relationship between directors	Not applicable
7	Affirmation that Director is not debarred from the holding office of director by virtue of any SEBI order or authority	Not applicable